M
Mario Boccadoro
Researcher at University of Turin
Publications - 670
Citations - 39049
Mario Boccadoro is an academic researcher from University of Turin. The author has contributed to research in topics: Multiple myeloma & Lenalidomide. The author has an hindex of 83, co-authored 638 publications receiving 34589 citations. Previous affiliations of Mario Boccadoro include Mount Sinai Hospital.
Papers
More filters
Journal ArticleDOI
Standard chemotherapy for myelomatosis: an area of great controversy.
TL;DR: The standard chemotherapy for MM will continue to be an area of great controversy until a new treatment strategy proves to be clearly superior in large randomized studies.
Journal ArticleDOI
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
Stefania Oliva,Davine Hofste op Bruinink,Davine Hofste op Bruinink,Lucie Rihova,Mattia D'Agostino,Lucia Pantani,Andrea Capra,Bronno van der Holt,Rossella Troia,Maria Teresa Petrucci,Tania Villanova,Pavla Všianská,Romana Jugooa,Claudia Brandt-Hagens,Milena Gilestro,Massimo Offidani,Rossella Ribolla,Monica Galli,Roman Hájek,Michele Cavo,Paola Omedè,Vincent H.J. van der Velden,Mario Boccadoro,Pieter Sonneveld +23 more
TL;DR: In this paper, the authors conducted an MRD correlative study of the EMN02/HO95 MM phase III trial in newly diagnosed MM patients achieving a suspected complete response before maintenance and every 6 months during maintenance.
Journal ArticleDOI
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Valentina Griggio,Francesca Perutelli,Chiara Salvetti,Elia Boccellato,Mario Boccadoro,Candida Vitale,Marta Coscia +6 more
TL;DR: A comprehensive overview of main immune defects affecting patients with CLL is provided, also describing the complex networks leading to immune evasion and tumor progression.
Journal ArticleDOI
Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study
Antonio Palumbo,Federica Cavallo,Izhar Hardan,Barbara Lupo,Valter Redoglia,Moshe Levin,Paolo Corradini,Sara Pezzatti,Francesca Patriarca,Michele Cavo,Magda Marcatti,Norbert Pescosta,Antonietta Falcone,Roberto Ria,Davide Rossi,Giulia Benevolo,Clotilde Cangialosi,Monica Galli,Lucio Catalano,Anna Baraldi,Angelo Michele Carella,A. M. Cafro,Agostina Siniscalchi,Claudia Crippa,Sara Grammatico,Maide Cavalli,Tommaso Caravita di Toritto,Francesco Di Raimondo,Arnon Nagler,Mario Boccadoro +29 more
TL;DR: Progression-free survival (PFS) was significantly prolonged in the MEL200 group in both standard-risk patients without t(4;14) or t(14;16) or del17p abnormalities and high- risk patients with t( 4;14), t( 14;16), or del 17p abnormalities.
Journal ArticleDOI
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies.
TL;DR: Results obtained with new-generation multidrug combinations in the treatment of high-risk smoldering MM and newly diagnosed MM are focused on, including the potential role of MRD and MRD-driven treatment strategies in clinical trials, in order to optimize and individualize treatment.